title: Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.
abstract: BACKGROUND
  Ciclosporin and oclacitinib are immunomodulators approved for the treatment of canine atopic dermatitis. The administration of a short course of prednisolone at the beginning of ciclosporin therapy hastens the efficacy of this drug; oclacitinib has a rapid antipruritic effect similar to that of prednisolone.
  
  
  OBJECTIVE
  To evaluate the oral tolerance of oclacitinib and ciclosporin given concurrently for three weeks.
  
  
  METHODS
  Two groups of eight beagles.
  
  
  METHODS
  Dogs were randomized to receive oclacitinib alone (0.4-0.6 mg/kg twice daily for 14 days then once daily for seven days) or in combination with ciclosporin (5 mg/kg once daily) for three weeks. They were examined every day and adverse events were recorded. Blood samples were collected during the acclimatization phase, weekly during treatment and at the end of the study for haematology, clinical chemistry and coagulation evaluation.
  
  
  RESULTS
  There were no abnormal clinical observations following treatment with oclacitinib given alone or concomitantly with ciclosporin, with the exception of diarrhoea in two dogs receiving both drugs. Three dogs from each group experienced transient inappetence; three dogs treated with oclacitinib had mild weight loss. Clinical pathology parameters remained within the reference range for beagle dogs at that facility.
  
  
  CONCLUSIONS
  The concomitant administration of ciclosporin and oclacitinib for three weeks to beagles was well tolerated and was not associated with an increase in the number of adverse events or laboratory abnormalities beyond those associated with oclacitinib given alone.
authors.affiliation: Elanco Centre de Recherche Santé Animale (CRA), 20 route de la petite glâne, CH 1566, St Aubin, Switzerland.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Panteri
authors.affiliation: Elanco Animal Health, Schwarzwaldallee 215, CH 4058, Basel, Switzerland.
authors.forename: Günther
authors.initials: G
authors.lastname: Strehlau
authors.affiliation: Elanco Animal Health, Schwarzwaldallee 215, CH 4058, Basel, Switzerland.
authors.forename: Rainer
authors.initials: R
authors.lastname: Helbig
authors.affiliation: Elanco Centre de Recherche Santé Animale (CRA), 20 route de la petite glâne, CH 1566, St Aubin, Switzerland.
authors.forename: Christine
authors.initials: C
authors.lastname: Prost
authors.affiliation: Elanco Animal Health, 2500 Innovation way, Greenfield, IN, 46140, USA.
authors.forename: Kelly
authors.initials: K
authors.lastname: Doucette
mesh_terms: D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D004283:Dog Diseases / Q000139:chemically induced*; D004285:Dogs; D004359:Drug Therapy, Combination; D005260:Female; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D007166:Immunosuppressive Agents; D011743:Pyrimidines; D013449:Sulfonamides; D016572:Cyclosporine; C588062:oclacitinib